Molecular Imaging: Page 73

FDA clears clinical trial for Blue Earth radiopharmaceutical

By AuntMinnie.com staff writers

The U.S. Food and Drug Administration (FDA) has given the go-ahead to Blue Earth Therapeutics to conduct a clinical study of its radiopharmaceutical labeled with lutetium-177 for treatment of metastatic, castrate-resistant prostate cancer.

April 11, 2022

CMS criticized for final decision on Aduhelm reimbursement

By Will Morton

The U.S. Centers for Medicare and Medicaid Services (CMS) finalized a plan April 7 that limits coverage of Biogen's Alzheimer's disease drug Aduhelm only to patients enrolled in clinical trials, despite pressure from the Society of Nuclear Medicine and Molecular Imaging and other groups to expand coverage of the drug.

April 7, 2022

Zr-89 tracer helps PET detect subtle prostate cancer lesions

By Will Morton

An experimental zirconium-89-based (Zr-89) PET radiotracer can detect tumors missed by existing tracers in patients whose cancer has returned after surgery or radiotherapy, according to a study published in the April 1 issue of the Journal of Nuclear Medicine.

April 7, 2022

CMS finalizes rule on limited payment for Alzheimer's drugs

By AuntMinnie.com staff writers

The U.S. Centers for Medicare and Medicaid Services (CMS) has issued a final national coverage determination that limits coverage for Alzheimer's monoclonal antibody drugs like aducanumab only to people enrolled in qualifying clinical trials.

April 6, 2022

PET/CT can reduce mediastinal cancer biopsies

By Will Morton

PET/CT scans can help prevent the use of invasive biopsies in patients with suspicious growths in the mediastinum, according to a study published April 1 in the Journal of Thoracic and Cardiovascular Surgery.

April 4, 2022

Syntermed is first U.S. distributor of Pylarify AI

By AuntMinnie.com staff writers

Imaging software developer Syntermed highlighted that it will be the first distributor in the U.S. of Pylarify AI, Lantheus Medical Imaging's artificial intelligence (AI) program for assisting standardized quantification of prostate-specific membrane antigen (PSMA)-PET/CT scans.

March 31, 2022

PET visualizes early atherosclerosis

By Will Morton

An experimental PET radiotracer can visualize immune cell activity in the artery walls of patients with atherosclerosis, a finding that could lead to a new approach for early diagnosis of the disease, according to a study published March 30 in Atherosclerosis.

March 31, 2022

German scientists develop method for less uranium waste

By AuntMinnie.com staff writers

Technical University of Munich scientists have developed a new processing method for molybdenum-99 (Mo-99) that results in significantly less waste from low-enriched uranium targets.

March 30, 2022

PET/MRI superior to MRI for diagnosing prostate cancer

By Will Morton

PET/MRI imaging with an experimental prostate-specific membrane antigen (PSMA) radiotracer appears superior to biparametric MRI alone for diagnosing primary prostate cancer, according to a study published March 28 in Prostate International.

March 30, 2022

DMS Health lands Vizient mobile imaging contract

By AuntMinnie.com staff writers

DMS Health Technologies has secured a mobile imaging supply contract with group purchasing organization Vizient.

March 28, 2022

GE announces first patient dosed with new PET radiopharmaceutical

By AuntMinnie.com staff writers

GE Healthcare announced that the first patient has been dosed in a phase III trial underway in France with a new dopamine transporter PET imaging radiopharmaceutical.

March 27, 2022

Week in Review: Virtual conference March 30-31 | New prostate treatment | COVID and cancer screening

By Brian Casey

March 25, 2022

Previous Page

Page 73 of 614

Next Page